Fieldview Capital Management LLC Has $1.65 Million Stock Holdings in Danaher Corporation $DHR

Fieldview Capital Management LLC raised its position in Danaher Corporation (NYSE:DHR) by 396.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,227 shares of the conglomerate’s stock after buying an additional 5,771 shares during the quarter. Fieldview Capital Management LLC’s holdings in Danaher were worth $1,654,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. JPL Wealth Management LLC acquired a new position in Danaher in the 3rd quarter valued at $25,000. Elevated Capital Advisors LLC acquired a new position in Danaher in the 4th quarter valued at $26,000. WFA of San Diego LLC acquired a new position in Danaher in the 2nd quarter valued at $26,000. ANTIPODES PARTNERS Ltd acquired a new position in Danaher in the 3rd quarter valued at $27,000. Finally, Hilton Head Capital Partners LLC acquired a new position in Danaher in the 4th quarter valued at $27,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of DHR stock opened at $179.95 on Monday. The company has a quick ratio of 1.52, a current ratio of 1.87 and a debt-to-equity ratio of 0.33. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a market cap of $127.37 billion, a P/E ratio of 34.81, a P/E/G ratio of 2.30 and a beta of 0.81. The business has a fifty day simple moving average of $180.93 and a 200 day simple moving average of $204.62.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, April 20th. The conglomerate reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.94 by $0.12. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $6 billion. During the same period in the prior year, the company earned $1.88 EPS. Danaher’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, sell-side analysts forecast that Danaher Corporation will post 8.45 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, June 26th. Danaher’s dividend payout ratio is currently 30.95%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of research reports. TD Cowen decreased their price objective on Danaher from $245.00 to $240.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Robert W. Baird decreased their price objective on Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Jefferies Financial Group reissued a “buy” rating and set a $245.00 target price on shares of Danaher in a report on Tuesday, April 21st. JPMorgan Chase & Co. reduced their target price on Danaher from $275.00 to $245.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. Finally, Wells Fargo & Company reduced their target price on Danaher from $240.00 to $212.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $233.61.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.